Annovis Bio Inc (US: ANVS) — Healthcare · Share Price, Chart & Market Data
About: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.74 (-3.87%)
ANVSAnnovis Bio Inc
Loading watchlist status…
Trade ANVS now
Annovis Bio Inc share price
ANVS price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 11:13 am GMT+0
ANVS price performance
-6.452%
5D
-14.286%
1M
-52.329%
YTD
12.258%
1Y
ANVS price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 11:13 am GMT+0
ANVS details
ANVS Market Signals